The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Genzyme; Heron; Regeneron; Squibb
Speakers' Bureau - Genzyme; Regeneron; Squibb
Research Funding - Novartis (Inst); Regeneron (Inst)
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
 
Aaron Scott Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
Other Relationship - Mesothelioma Applied Research Foundation
 
Austin Goodrich
No Relationships to Disclose
 
Nathan R. Foster
No Relationships to Disclose
 
Panos Savvides
No Relationships to Disclose
 
Liza C Villaruz
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; InterVenn Biosciences; Janssen Oncology; Jazz Pharmaceuticals; Sanofi/Regeneron; Takeda
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); BMS (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst); Regeneron (Inst)
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; Ascendis Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CureVac; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; Fosun Pharma; G1 Therapeutics; Genentech; Gilead Sciences; ITeos Therapeutics; Janssen; Merck; Novartis; Regeneron; Sanofi; Surface Oncology; Synthekine; Teva
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst); Regeneron
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Paul Bernard Romesser
Consulting or Advisory Role - EMD Serono; Faeth Therapeutics; Natera
Research Funding - X-RAD Therapeutics (Inst)
 
Diane Feldman
No Relationships to Disclose
 
Liang Cao
No Relationships to Disclose
 
Mary M. Salvatore
Research Funding - Abbvie; BioClinica; Boehringer Ingelheim (Inst); Genentech (Inst); LungLife AI
 
Anja C. Roden
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Speakers' Bureau - Alkermes (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Sorrento Therapeutics (Inst); Vyriad (Inst)
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; KLJ Associates; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); TP Therapeutics (Inst); verastem (Inst)
 
Pamela N. Munster
No Relationships to Disclose
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - AADi; Agenus; Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Boehringer Ingelheim; Concarlo; Ellipses Pharma; Epizyme; Gencirq; Ipsen; January Therapeutics; Kirilys Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Boehringer Ingelheim; Epizyme; Epizyme; Epizyme
 
Travis Edward Grotz
No Relationships to Disclose